Claims for Patent: 7,056,513

Summary for Patent: 7,056,513

Title:	Telomerase
Abstract:	The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.
Inventor(s):	Cech; Thomas R. (Boulder, CO), Lingner; Joachim (Epalinges, CH), Nakamura; Toru (Boulder, CO), Chapman; Karen B. (Sausalito, CA), Morin; Gregg B. (Palo Alto, CA), Harley; Calvin B. (Palo Alto, CA), Andrews; William H. (Richmond, CA)
Assignee:	Geron Corporation (Menlo Park, CA) Regents of the University of Colorado (Boulder, CO)
Application Number:	09/843,676
Patent Claims:	1. An isolated polypeptide that induces anti-hTRT specific antibody, consisting of 10 or more consecutive amino acids of SEQ. ID NO:225. 2. The polypeptide of claim 1, containing an amino acid sequence selected from SEQ. ID NO:112, SEQ. ID NO:113, SEQ. ID NO:114, SEQ. ID NO:115, SEQ. ID NO:116, and SEQ. ID NO;117. 3. The polypeptide of claim 1, which does not retain the telomerase catalytic activity of native human telomerase reverse transcriptase. 4. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier. 5. An immunogenic composition that induces anti-hTRT specific antibody, comprising a peptide and an adjuvant, wherein the peptide consists of 10 or more consecutive amino acids of SEQ. ID NO:225. 6. The composition of claim 5, wherein the adjuvant is selected from Freund's adjuvant, an mineral gel, aluminum hydroxide, lysolecithin, pluronic polyol, a polyanlon, a peptide, an oil emulsion, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP), Bacillus Calmette-Guerin, and Corynebacterium parvum. 7. A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject the composition of claim 5. 8. The method of claim 7, further comprising assessing whether telomerase-specific antibody is produced as a result of the administration. 9. An immunogenic composition that induces anti-hTRT specific antibody, comprising a peptide and an adjuvant, wherein the peptide consists of 5 to 10 consecutive amino acids of SEQ. ID NO:225. 10. The composition of claim 9, wherein the adjuvant is selected from Freund's adjuvant, an mineral gel, aluminum hydroxide, lysolecithin pluronic polyol, a polyanion, a peptide, an oil emulsion, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP), Bacillus Calmette-Guerin, and Corynebacterium parvum. 11. A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject the composition of claim 9. 12. The method of claim 7, further comprising assessing whether telomerase-specific antibody is produced as a result of the administration. 13. The polypeptide of claim 1, produced by recombinant expression. 14. The polypeptide of claim 1, produced by chemical synthesis. 15. A chimeric molecule comprising: a potypeptide that consists of 10 or more consecutive amino acids of SEQ. ID NO:225, and an immunogenic second protein, wherein the polypeptide is fused to the second protein so as to form a chimeric molecule that induces anti-hTRT specific antibody. 16. The chimeric protein of claim 15, wherein the second protein is keyhole limpet hemocyanin. 17. An immunogenic composition comprising the chimeric protein of claim 15, and an adjuvant. 18. A chimeric molecule comprising: a polypeptide that consists of 5 to 10 consecutive amino acids of SEQ. ID NO:225, and an immunogenic second protein, wherein the polypeptide is fused to the second protein so as to form a chimeric molecule that induces anti-hTRT specific antibody. 19. The chimeric protein of claim 18, wherein the second protein is keyhole limpet hemocyanin. 20. An immunogenic composition comprising the chimeric protein of claim 18, and an adjuvant.

Details for Patent 7,056,513

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2016-10-01